Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novamind Inc (OP:NVMDF)

N/A UNCHANGED
Last Price Updated: 3:36 PM EDT, Jun 13, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novamind Inc

< Previous 1 2 3 Next >
News headline image
Novamind Opens 6th Integrative Psychiatry Clinic, Adds 3rd Clinical Research Site
TORONTO, ON / ACCESSWIRE / September 30, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is... 
From Novamind Inc.
Via AccessWire
News headline image
Novamind Announces DTC Eligibility for its Common Shares
TORONTO, ON / ACCESSWIRE / September 24, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is... 
From Novamind Inc.
Via AccessWire
News headline image
Novamind to Present at Benzinga Healthcare Conference
Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare TORONTO, ON / ACCESSWIRE / September 23, 2021 / Novamind Inc.... 
From Novamind Inc.
Via AccessWire
News headline image
Novamind Announces Inclusion in NYSE Listed AdvisorShares Psychedelics ETF
TORONTO, ON / ACCESSWIRE / September 20, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is... 
From Novamind Inc.
Via AccessWire
News headline image
Novamind to Present at Life Sciences Investor Forum
TORONTO, ON / ACCESSWIRE / September 14, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is... 
From Novamind Inc.
Via AccessWire
News headline image
Novamind to Serve as Research Site for Karuna Therapeutics Late-Stage Clinical Trial
Cedar Clinical Research to Host Phase III Trial for Investigational Therapy for Schizophrenia TORONTO, ON / ACCESSWIRE / September 13, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or... 
From Novamind Inc.
Via AccessWire
News headline image
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry? ↗
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate... 
Via Benzinga
News headline image
Novamind Uplists to OTCQB Venture Market
TORONTO, ON / ACCESSWIRE / September 9, 2021 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is... 
From Novamind Ventures Inc.
Via AccessWire
News headline image
Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference
TORONTO, ON / ACCESSWIRE / September 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is... 
From Novamind Inc.
Via AccessWire
News headline image
Psychedelic Drug Industry Report Card For 2021 ↗
In assessing the psychedelic drug industry, a primary focus for investors is drug development. 
Via Talk Markets
News headline image
Novamind Divests Non-Core Retreat Investment
TORONTO, ON / ACCESSWIRE / August 11, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today... 
From Novamind Inc.
Via AccessWire
News headline image
Which Psychedelic Drug Has The Most Commercial Potential? ↗
As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis. 
Via Talk Markets
News headline image
Novamind Strengthens Mental Health Expertise, Adds Communications Leader
Samantha DeLenardo joins from CAMH, Canada's largest mental health teaching hospital and leader in mental health research TORONTO, ON / ACCESSWIRE / August 6, 2021 / Novamind Inc., (CSE:NM)(OTC... 
From Novamind Inc.
Via AccessWire
News headline image
Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected ↗
Last week in Psychedelics: 
Via Benzinga
News headline image
Novamind Opens 5th Clinic Location Specialized in Integrative Psychiatry for Patients with Treatment-Resistant Conditions
Company executes organic growth mandate, on track to open four new clinics by Q3 2021 TORONTO, ON / ACCESSWIRE / July 29, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the... 
From Novamind Inc.
Via AccessWire
News headline image
Novamind Has Applied to Have its Common Shares Posted for Trading on the OTCQB in the United States
Aims to increase visibility and facilitate investment for United States investors TORONTO, ON / ACCESSWIRE / July 21, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the... 
From Novamind Inc.
Via AccessWire
News headline image
Novamind Selected as Research Site for Bionomics' PTSD Clinical Trial
Cedar Clinical Research to Host Phase IIb Trial for a Novel PTSD Treatment TORONTO, ON / ACCESSWIRE / July 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a... 
From Novamind Inc.
Via AccessWire
News headline image
Novamind Launches Psychedelic Therapy Frontiers Podcast
Aimed at an audience of psychedelic medicine researchers and clinicians TORONTO, ON / ACCESSWIRE / June 30, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a... 
From Novamind Inc.
Via AccessWire
News headline image
Novamind Welcomes Dr. Paul Thielking as Chief Scientific Officer
- Led first-of-its-kind study of group psilocybin therapy for cancer patients with depression - Co-Investigator on a study to evaluate ketamine as a treatment for opioid use disorder - Will lead... 
From Novamind Inc.
Via AccessWire
Topics Death
News headline image
Novamind Announces US$1,000,000 Strategic Investment in Stealth Mode Drug Development Company
TORONTO, ON / ACCESSWIRE / June 17, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announces... 
From Novamind Inc.
Via AccessWire
News headline image
Novamind to Present at the H.C. Wainwright Psychedelics Conference on June 17, 2021
Novamind to be featured in panel discussions on the disruptive potential of psychedelic treatments TORONTO, ON / ACCESSWIRE / June 15, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind"... 
From Novamind Inc.
Via AccessWire
News headline image
Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers ↗
Atai Launches $214 Million Nasdaq IPO Offering Psychedelics biotech platform Atai life Sciences has announced an initi... 
Via Benzinga
Topics Initial Public Offering
News headline image
Novamind Launches Psychedelic Therapy Protocol for Frontline Healthcare Workers
Novamind and the Wholeness Center to launch clinical offering in Utah and Colorado TORONTO, ON / ACCESSWIRE / June 10, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the... 
From Novamind Inc.
Via AccessWire
News headline image
Novamind Reports Fiscal Q3 Financial Results and Operating Highlights
- Revenue of $1,846,132 for Fiscal Q3 2021, +43% quarter-over-quarter - Announced doubling of clinic network by September 2021 - Forecasting 65,000 clinic visits in 2021, +225% year-over-year TORONTO,... 
From Novamind Inc.
Via AccessWire
News headline image
Video: Experts Discuss Use Of Psychedelics In Mental Health Settings ↗
The psychedelics industry has started to gain serious traction and is attracting lots of attention these days. However, what many people may not kn... 
Via Benzinga
News headline image
Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M ↗
Last week, the psychedelics space was moved by results from the world’s first Phase 3 clinical study of a scheduled psychedelic compound... 
Via Benzinga
News headline image
Novamind And Field Trip Expand Footprint Of Psychedelic Clinics ↗
Novamind Inc. (OTC:NVMDF), a company specializing in mental ... 
Via Benzinga
News headline image
Novamind Announces Participation at the Planet MicroCap Showcase on April 20 - 22, 2021
TORONTO, ON / ACCESSWIRE / April 20, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, will... 
From Novamind Inc.
Via AccessWire
News headline image
Novamind to Present at the Planet MicroCap Virtual Event on April 22, 2021
TORONTO, ON / ACCESSWIRE / April 19, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, will... 
From Novamind Inc.
Via AccessWire
News headline image
Keynotes, Educational Panels and 66 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on April 20-22, 2021
LOS ANGELES, CA / ACCESSWIRE / April 19, 2021 / The Planet MicroCap Showcase will take place on April 20-22, 2021, where 66 SmallCap, MicroCap and NanoCap public and private companies will be... 
From Stock News Now
Via AccessWire
Topics Cannabis
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.